Drug Trial Radar · NCT00261911
A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.
Last checked: Nov 20, 2026Latest source record: Aug 31, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
498
Actual
Start
Jul 2000
Primary completion
Not stated
Study completion Feb 2002
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.
Conditions
- Obesity
Interventions
sibutramineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change in body mass index (BMI) from baseline to endpoint.Time frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.